Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Ask the Experts: Influenza: Contraindications & Precautions

Results (10)

Yellow fever vaccine is contraindicated for people who have a history of a severe (anaphylactic) allergy to eggs.

CDC and medical societies issuing vaccination recommendations do not consider egg allergy of any severity to be a contraindication or precaution to egg-based influenza vaccines. A person with egg allergy of any severity may receive any influenza vaccine that is appropriate for the person’s age and health status. When administering an egg-based influenza vaccine to a person with egg allergy of any severity, no additional safety precautions are needed, beyond those recommended when administering any vaccine to any recipient. 
 

Last reviewed: September 23, 2026

Contraindications to egg-based inactivated influenza vaccines (IIV) are a severe allergic reaction to a prior dose of any non-mRNA influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of any valency) or a severe allergy to an influenza vaccine component (except egg). CDC and medical societies recommend that people with egg allergy of any severity (but no history of allergy to the influenza vaccine or an influenza vaccine component) may receive any influenza vaccine appropriate for their age and health status.

Precautions to egg-based IIV include moderate or severe acute illness, and history of Guillain-Barré syndrome within 6 weeks after a dose of influenza vaccine.

Contraindications to cell culture-based IIV (ccIIV) are a history of a severe allergic reaction to a previous dose of ccIIV or any component of ccIIV.

Precautions to ccIIV are moderate or severe acute illness, a history of Guillain-Barré syndrome within 6 weeks after a dose of any non-mRNA influenza vaccine, and a history of a severe allergic reaction to a previous dose of another type of influenza vaccine (e.g., any egg-based IIV, RIV, or LAIV).

Contraindications to RIV are a history of a severe allergic reaction to a previous dose of RIV or any component of RIV.

Precautions to RIV are moderate or severe acute illness, a history of Guillain-Barré syndrome within 6 weeks after a dose of any non-mRNA influenza vaccine, and a history of a severe allergic reaction to a previous dose of another type of influenza vaccine other than an mRNA vaccine (e.g., any egg-based IIV, ccIIV, or LAIV).

The components of mFlusiva mRNA influenza vaccine are different from other influenza vaccines. It contains no influenza antigens. The only contraindication listed on its package insert is a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of mFlusiva or a component of it (e.g., polyethylene glycol, PEG). The only precaution to its use is a moderate or severe acute illness, with or without fever (defer vaccination until symptoms are resolving). It is not licensed for use during pregnancy because there are insufficient data available on its use during pregnancy.

Last reviewed: October 11, 2026

A severe allergic reaction to an influenza vaccine is a contraindication to receiving another dose of the same vaccine and may be a contraindication or precaution for other influenza vaccine types. The following table summarizes CDC guidance for egg-based IIV and LAIV, cell culture-based IIV, and recombinant vaccine. CDC’s September 2026 interim clinical considerations did not change this guidance. See www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html.

For mFlusiva, FDA lists a severe allergic reaction to any component as a contraindication. A severe allergic reaction to other non-mRNA influenza vaccines is neither a contraindication nor a precaution to its use. See www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva.

Vaccine (of any valency) associated with previous serious or anaphylactic reaction Available 2026-27 influenza vaccines
Egg-based IIVs
and LAIV		 Cell-culture- based IIV: ccIIV (Flucelvax) Recombinant IIV: RIV (Flublok)
Any egg-based IIV or LAIV Contraindication Precaution † Precaution †
Any ccIIV Contraindication Contraindication Precaution †
Any RIV Contraindication Precaution † Contraindication
Unknown influenza vaccine Allergist consultation recommended

† Note regarding patients having either of the above precautions for either ccIIV or IIV: use of ccIIV and RIV in such instances should occur in an inpatient or outpatient medical setting under the supervision of a healthcare provider (HCP) who can recognize and manage severe allergic reaction; HCPs should consider consulting with an allergist to help identify the vaccine component responsible for the reaction.

Last reviewed: October 11, 2026

Contraindications to LAIV are:

  • a history of severe allergic reaction to a vaccine component (except egg) or after a previous dose of any non-mRNA influenza vaccine (people with egg allergy of any severity may receive LAIV if it is otherwise appropriate for their age and health status)
  • concomitant aspirin- or salicylate-containing therapy in children and adolescents because of the risk of Reye syndrome
  • children age 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a healthcare provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode during the preceding 12 months
  • immunosuppression due to any cause, including medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asplenia or functional asplenia (e.g., due to sickle cell anemia)
  • cranial cerebral spinal fluid (CSF) leak or cochlear implant (due to potential for CSF leak)
  • close contacts and caregivers of severely immunosuppressed people who require a protected environment
  • pregnancy
  • receipt of influenza antiviral medication within the previous 48 hours (for oseltamivir or zanamivir), previous 5 days (for peramivir), or previous 17 days (for baloxavir)

Precautions are:

  • moderate or severe acute illness with or without fever (defer)
  • history of Guillain-Barré syndrome within 6 weeks after a dose of influenza vaccine
  • asthma in a person age 5 years or older
  • underlying medical conditions that might predispose to complications after influenza virus infection, such as chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)
Last reviewed: October 11, 2026

Everyone age 6 months of age or older with egg allergy and no contraindication to vaccination should receive an influenza vaccine. Any influenza vaccine (egg based or non-egg based) appropriate for the person’s age and health status can be used.

Egg allergy alone does not require any additional safety measures for influenza vaccination beyond those recommended for any recipient of any vaccine. As a general principle, all vaccines should be administered in settings in which personnel and equipment needed for rapid recognition and treatment of acute hypersensitivity reactions are available.

For more on the evidence and rationale supporting ACIP’s recommendations regarding influenza vaccination and egg allergy, see pages 12 and 13 of the ACIP recommendations for the 2023–24 season at www.cdc.gov/mmwr/volumes/72/rr/pdfs/rr7202a1-H.pdf.

Last reviewed: October 11, 2026


2:01

View All Video Questions

Last reviewed: September 3, 2025

No.

Last reviewed: October 11, 2026

Yes, you can. Some, but not all, studies have reported increased rates of febrile seizures among children, especially those age 12 through 23 months, who received simultaneous vaccination with IIV and pneumococcal conjugate vaccine (PCV13, Pfizer) or DTaP vaccine (Daptacel, Infanrix, Pediarix, Pentacel), when compared with children who received these vaccines separately. However, because of the risks associated with delaying either of these vaccines, ACIP does not recommend administering them at separate visits or deviating from the recommended vaccine schedule in any way. The risk of febrile seizure following coadministration of influenza vaccine with currently recommended PCV15 or PCV20 vaccines has not been evaluated.

Febrile seizures may be triggered by any cause of fever and occur in up to 5% of all children They are generally benign. Healthcare providers should be prepared to answer parents’ questions about febrile seizures and fever when discussing vaccinations. Here is a CDC resource that addresses these concerns: www.cdc.gov/vaccine-safety/about/febrile-seizures.html.

Last reviewed: October 11, 2026

The probability of a serious allergic reaction following any vaccine is extremely low if the person is properly screened. ACIP has not issued a recommendation that desensitization injections and vaccines be separated by any specific time period; consequently, we feel that you should take the opportunity to vaccinate.

Last reviewed: October 11, 2026

Yes. A history of GBS unrelated to influenza vaccine is not a contraindication or precaution to influenza vaccination. GBS within 6 weeks following a previous dose of influenza vaccine is considered a precaution for use of influenza vaccines.

Last reviewed: October 11, 2026

This page was updated on .

Our Affiliated Sites

For the Public: VaccineInformation.org
For Coalitions: ImmunizationCoalitions.org
Let's Get Real
Information about pediatric vaccines for parents and providers.
65+ Flu Defense
Protect vulnerable, older adult patients from influenza.
Give2MenACWY.org
Improve protection from meningococcal serogroups ACWY.
NAIIS
Home of the National Adult and Influenza Immunization Summit.